{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:19:45Z","timestamp":1787505585056,"version":"build-2736575974"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:00:00Z","timestamp":1768435200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:00:00Z","timestamp":1768435200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005296","name":"Universit\u00e4tsklinikum Regensburg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005296","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an extremely rare hematologic malignancy with an aggressive course and poor prognosis. Treatment remains challenging particularly in patients who are ineligible for stem cell transplantation due to resistance to conventional chemotherapy. The introduction of tagraxofusp, a CD123-directed cytotoxin, has significantly expanded therapeutic options and improved outcomes for patients with BPDCN. However, its use can be accompanied by notable adverse events, especially capillary leak syndrome, underscoring the need for careful patient selection and monitoring. Up to date, no data is available regarding the safety of tagraxofusp in patients with chronic kidney failure and cardiovascular co-morbidities. We present the case of a 79-year-old male who developed a solitary, rapidly progressing skin lesion on his lower back. The lesion represented the first manifestation of BPDCN with bone marrow infiltration and concomitant myelodysplastic syndrome (MDS). Molecular analysis identified mutations in CBL, TET2, ZRSR2 and KRAS. Non-eligible for stem cell transplantation, the patient was admitted to treatment with tagraxofusp in a dose-reduced protocol due to concomitant chronic kidney disease (CKD). After three doses of the first cycle, treatment needed to be stopped due to acute-on-chronic renal failure. After treatment disruption, kidney failure was completely restituted to pre-treatment levels. Notably, skin and bone marrow biopsies demonstrated a dermatologic complete response and partial remission of bone marrow infiltration. A watch and wait concept was followed, and prolonged therapy response was obtained for 8 months before relapse. To our knowledge, this is the first reported case demonstrating the use of tagraxofusp in a patient with BPDCN and advanced chronic kidney disease, showing that even a minimum of tolerated treatment dose can induce a sustained response. Despite the risk of adverse events, tagraxofusp should be considered a viable treatment option for elderly patients with poor performance status and significant comorbidities who are ineligible for intensive chemotherapy or stem cell transplantation, as even limited exposure may achieve meaningful clinical responses.<\/jats:p>","DOI":"10.1007\/s00277-026-06794-8","type":"journal-article","created":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T01:57:28Z","timestamp":1768442248000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Sustained response to minimal-dose tagraxofusp in a patient with BPDCN and advanced chronic kidney disease"],"prefix":"10.1007","volume":"105","author":[{"given":"Christina","family":"Brummer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Evert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Keil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Grube","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Herr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Radsak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,15]]},"reference":[{"issue":"19","key":"6794_CR1","doi-asserted-by":"publisher","first-page":"4838","DOI":"10.1182\/bloodadvances.2020002474","volume":"4","author":"K Laribi","year":"2020","unstructured":"Laribi K, De Baugier A, Sobh M, Cerroni L, Valentini CG, Aoki T et al (2020) Blastic plasmacytoid dendritic cell neoplasms: results of an international survey on 398 adult patients. Blood Adv 4(19):4838\u20134848","journal-title":"Blood Adv"},{"issue":"9","key":"6794_CR2","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1038\/s41375-023-01968-z","volume":"37","author":"B Cuglievan","year":"2023","unstructured":"Cuglievan B, Connors J, He J, Khazal S, Yedururi S, Dai J et al (2023) Blastic plasmacytoid dendritic cell neoplasm: a comprehensive review in pediatrics, adolescents, and young adults (AYA) and an update of novel therapies. Leukemia 37(9):1767\u20131778","journal-title":"Leukemia"},{"issue":"2","key":"6794_CR3","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/modpathol.2015.145","volume":"29","author":"F Facchetti","year":"2016","unstructured":"Facchetti F, Cigognetti M, Fisogni S, Rossi G, Lonardi S, Vermi W (2016) Neoplasms derived from plasmacytoid dendritic cells. Mod Pathol 29(2):98\u2013111","journal-title":"Mod Pathol"},{"issue":"7","key":"6794_CR4","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1038\/s41375-022-01625-x","volume":"36","author":"IA Cree","year":"2022","unstructured":"Cree IA (2022) The WHO classification of haematolymphoid tumours. Leukemia 36(7):1701\u20131702","journal-title":"Leukemia"},{"issue":"2","key":"6794_CR5","doi-asserted-by":"publisher","first-page":"239","DOI":"10.3324\/haematol.2012.072645","volume":"98","author":"L Pagano","year":"2013","unstructured":"Pagano L, Valentini CG, Pulsoni A, Fisogni S, Carluccio P, Mannelli F et al (2013) Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study. Haematologica 98(2):239\u2013246","journal-title":"Haematologica"},{"issue":"16","key":"6794_CR6","doi-asserted-by":"publisher","first-page":"4020","DOI":"10.1182\/bloodadvances.2019000173","volume":"4","author":"N Pemmaraju","year":"2020","unstructured":"Pemmaraju N, Konopleva M (2020) Approval of tagraxofusp-erzs for blastic plasmacytoid dendritic cell neoplasm. Blood Adv 4(16):4020\u20134027","journal-title":"Blood Adv"},{"key":"6794_CR7","doi-asserted-by":"crossref","unstructured":"Luskin MR, Lane AA (2023) Tagraxofusp for blastic plasmacytoid dendritic cell neoplasm. Haematologica [Internet]. [cited 2025 Aug 20]; Available from: https:\/\/haematologica.org\/article\/view\/haematol.2022.282171","DOI":"10.3324\/haematol.2022.282171"},{"key":"6794_CR8","unstructured":"Stemline Prescribing Information of Elzonris (Tagraxofusp) [Internet]. [cited 2025 Aug 20]. Available from: https:\/\/ec.europa.eu\/health\/documents\/community-register\/2022\/20221014157344\/anx_157344_en.pdf"},{"key":"6794_CR9","doi-asserted-by":"crossref","unstructured":"Faysman M, Aocnp D-CK, Rubin, Np J, Lubas P-CA, Kujawa PDT, Hinojosa PD, Bcop G, Marx R, PharmD, Bcop K et al (2025) Care optimization for patients with blastic plasmacytoid dendritic cell neoplasm receiving tagraxofusp. J Adv Pract Oncol [Internet]. [cited 2025 Aug 20];16(7). Available from: https:\/\/jadpro.com\/online-first\/2025\/care-optimization-for-patients-with-blastic-plasmacytoid-dendritic-cell-neoplasm-receiving-tagraxofusp\/","DOI":"10.6004\/jadpro.2025.16.7.21"},{"key":"6794_CR10","doi-asserted-by":"publisher","first-page":"1384172","DOI":"10.3389\/fonc.2024.1384172","volume":"14","author":"P Faustmann","year":"2024","unstructured":"Faustmann P, Schroeder JC, Mix L, Harland L, Riedel A, Vogel W et al (2024) Real-world evidence on Tagraxofusp for blastic plasmacytoid dendritic cell neoplasm \u2013 collected cases from a single center and case reports. Front Oncol 14:1384172","journal-title":"Front Oncol"},{"issue":"17","key":"6794_CR11","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1056\/NEJMoa1815105","volume":"380","author":"N Pemmaraju","year":"2019","unstructured":"Pemmaraju N, Lane AA, Sweet KL, Stein AS, Vasu S, Blum W et al (2019) Tagraxofusp in blastic plasmacytoid Dendritic-Cell neoplasm. N Engl J Med 380(17):1628\u20131637","journal-title":"N Engl J Med"},{"issue":"22","key":"6794_CR12","doi-asserted-by":"publisher","first-page":"19204","DOI":"10.18632\/oncotarget.4146","volume":"6","author":"L Mart\u00edn-Mart\u00edn","year":"2015","unstructured":"Mart\u00edn-Mart\u00edn L, L\u00f3pez A, Vidriales B, Caballero MD, Rodrigues AS, Ferreira SI et al (2015) Classification and clinical behavior of blastic plasmacytoid dendritic cell neoplasms according to their maturation-associated immunophenotypic profile. Oncotarget 6(22):19204\u201319216","journal-title":"Oncotarget"},{"key":"6794_CR13","unstructured":"Stemline Capillary Leak Syndrome (CLS) Management guide: Elzonris [Internet]. [cited 2025 Aug 20]. Available from: https:\/\/www.elzonris.com\/hcp\/content\/documents\/ELZONRIS_CLS_Management_Guide_update.pdf"},{"issue":"10","key":"6794_CR14","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1182\/bloodadvances.2022007879","volume":"7","author":"H Beird","year":"2023","unstructured":"Beird H, Yin CC, Khoury JD, Pierce S, Abbas HA, Zhao L et al (2023) TET2 truncating mutations predict a worse outcome in blastic plasmacytoid dendritic cell neoplasm. Blood Adv 7(10):2000\u20132003","journal-title":"Blood Adv"},{"issue":"1","key":"6794_CR15","doi-asserted-by":"publisher","first-page":"495","DOI":"10.18632\/oncotarget.28742","volume":"16","author":"F Fei","year":"2025","unstructured":"Fei F, Telatar M, Tomasian V, Chang L, Danilova O, Arias-Stella J et al (2025) Genetic characteristics of blastic plasmacytoid dendritic cell neoplasm: A single institution experience. Oncotarget 16(1):495\u2013507","journal-title":"Oncotarget"},{"key":"6794_CR16","doi-asserted-by":"publisher","first-page":"1432545","DOI":"10.3389\/fphar.2024.1432545","volume":"15","author":"J Ren","year":"2024","unstructured":"Ren J, Lv L, Tao X, Zhai X, Chen X, Yu H et al (2024) The role of CBL family ubiquitin ligases in cancer progression and therapeutic strategies. Front Pharmacol 15:1432545","journal-title":"Front Pharmacol"},{"issue":"4","key":"6794_CR17","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s12185-023-03597-9","volume":"118","author":"K Fukuchi","year":"2023","unstructured":"Fukuchi K, Koyama D, Takada M, Mori H, Hayashi K, Asano N et al (2023) Mutated ZRSR2 and CUL3 accelerate clonal evolution and confer venetoclax resistance via RAS signaling pathway in blastic plasmacytoid dendritic cell neoplasm. Int J Hematol 118(4):489\u2013493","journal-title":"Int J Hematol"},{"issue":"15","key":"6794_CR18","doi-asserted-by":"publisher","first-page":"6404","DOI":"10.18632\/oncotarget.2223","volume":"5","author":"A Stenzinger","year":"2014","unstructured":"Stenzinger A, Endris V, Pfarr N, Andrulis M, J\u00f6hrens K, Klauschen F et al (2014) Targeted ultra-deep sequencing reveals recurrent and mutually exclusive mutations of cancer genes in blastic plasmacytoid dendritic cell neoplasm. Oncotarget 5(15):6404\u20136413","journal-title":"Oncotarget"},{"issue":"5","key":"6794_CR19","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1038\/s41375-022-01538-9","volume":"36","author":"M Khanlari","year":"2022","unstructured":"Khanlari M, Yin CC, Takahashi K, Lachowiez C, Tang G, Loghavi S et al (2022) Bone marrow clonal hematopoiesis is highly prevalent in blastic plasmacytoid dendritic cell neoplasm and frequently sharing a clonal origin in elderly patients. Leukemia 36(5):1343\u20131350","journal-title":"Leukemia"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06794-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-06794-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06794-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T03:32:49Z","timestamp":1770262369000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-06794-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,15]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["6794"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-06794-8","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,15]]},"assertion":[{"value":"11 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was waived by the University of Regensburg (Ref. No. 25-4323-180). The preparation of this report was conducted in accordance with the principles of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was obtained from the patient for publication of this case report.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18"}}